Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Pyxis Oncology is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) and immunotherapies for solid tumors. The company's lead asset, PYX-201, is an ADC targeting solid tumors with high expression of specific antigens, currently in Phase 1/2 trials. With minimal revenue, a $100M market cap, and negative cash flow of $100M annually, Pyxis is a high-risk, binary-outcome development story dependent on clinical trial readouts and capital markets access.
Pyxis operates a classic biotech R&D model: raise capital through equity offerings and debt, invest in clinical trials to demonstrate safety/efficacy, then either commercialize approved drugs or out-license to larger pharma partners. The company's ADC platform targets differentiated mechanisms in solid tumors, aiming to achieve better efficacy/safety profiles than existing therapies. Monetization depends entirely on successful clinical development, FDA approval, and either building commercial infrastructure or securing lucrative partnership deals with 10-20% royalties plus $500M+ in potential milestones.
Clinical trial data releases - particularly Phase 1/2 safety, tolerability, and preliminary efficacy signals for PYX-201
Regulatory milestones - IND filings for new programs, FDA feedback on trial designs, breakthrough therapy designations
Capital raises and cash runway updates - equity offerings dilute shareholders but extend operational runway; stock typically drops 20-40% on dilutive financings
Partnership announcements - licensing deals, collaborations with big pharma validate platform and provide non-dilutive funding
Competitive landscape shifts - competitor trial failures increase relative positioning; competitor successes create sector momentum or highlight Pyxis's disadvantages
Clinical trial failure risk - oncology drugs have ~5% Phase 1 to approval success rates; single negative readout can render company worthless overnight
Capital markets dependency - with 4.29x current ratio and ~$100M annual burn, Pyxis needs access to equity markets every 12-18 months; prolonged biotech bear markets (like 2022-2023) can force fire-sale asset liquidations
Regulatory pathway uncertainty - FDA standards for ADC approvals evolving; accelerated approval pathways require careful endpoint selection and may face post-marketing requirements
Crowded ADC landscape - AbbVie, Daiichi Sankyo, AstraZeneca, Gilead dominate with approved ADCs and deep pipelines; Pyxis must demonstrate differentiated efficacy/safety to compete
Big pharma in-house development - large oncology players increasingly developing ADCs internally rather than acquiring small biotechs, reducing exit optionality
Platform technology risk - if Pyxis's ADC linker/payload technology proves inferior to competitors' approaches, entire pipeline value collapses
Dilution risk - at $100M market cap with $100M annual burn, equity raises of 50-100% of market cap are likely within 12 months, severely diluting existing shareholders
Going concern risk - if clinical data disappoints and capital markets close, company may lack resources to complete trials or may liquidate at distressed valuations
Minimal revenue cushion - unlike commercial-stage biotechs with product sales to partially fund R&D, Pyxis is entirely dependent on external capital
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by scientific milestones, not economic cycles. However, capital markets access is highly cyclical: during recessions or risk-off periods, small-cap biotech equity financing becomes difficult or impossible, forcing companies to accept punitive terms or halt operations.
Rising interest rates negatively impact Pyxis through multiple channels: (1) Higher discount rates compress NPV of far-future cash flows, disproportionately hurting pre-revenue biotechs trading on 2028+ earnings potential; (2) Risk-free rate competition makes speculative biotech less attractive versus bonds; (3) Reduced investor risk appetite during tightening cycles decreases biotech sector liquidity. The 2022-2023 rate hiking cycle devastated small-cap biotech valuations, with many trading below cash value. Conversely, rate cuts in 2024-2025 improved financing conditions.
Minimal direct credit exposure - Pyxis has limited debt (0.28 D/E ratio) and doesn't rely on credit markets for operations. However, broader credit conditions affect: (1) Biotech sector M&A activity as acquirers' cost of capital changes; (2) Venture capital and crossover fund deployment into private/public biotech; (3) Partnership economics as big pharma's financing costs influence deal structures.
growth/speculative - Attracts venture-style investors seeking 5-10x returns from clinical success, biotech-specialized hedge funds with scientific expertise to evaluate trial designs, and retail momentum traders during positive data catalysts. Not suitable for value or income investors given negative earnings, no dividends, and binary risk profile. The -67.5% three-month decline reflects typical clinical-stage volatility.
high - Clinical-stage biotech exhibits extreme volatility with 50-80% single-day moves on trial data. The stock's 18.1% one-year return masks multiple 40%+ swings. Beta likely exceeds 2.0x relative to broader market. Liquidity constraints at $100M market cap amplify volatility as small order flows move prices significantly.
